TY - JOUR
T1 - Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
AU - Segalés Coma, Joaquim
AU - Clotet Sala, Bonaventura
AU - Barreiro, Antonio
AU - Prenafeta, Antoni
AU - Bech-Sabat, Gregori
AU - Roca, Mercè
AU - Mur, Eva Perozo
AU - March, Ricard
AU - González-González, Luis
AU - Madrenas, Laia
AU - Corominas, Júlia
AU - Fernández, Alex
AU - Moros, Alexandra
AU - Cañete, Manuel
AU - Molas, Mercè
AU - Pentinat-Pelegrin, Thais
AU - Panosa, Clara
AU - Moreno, Alberto
AU - Molas, Ester Puigvert
AU - Vilarrassa, Eva Pol
AU - Palmada, Jordi
AU - Garriga, Carme
AU - Cabañas, Teresa Prat
AU - Iglesias-Fernández, Javier
AU - Vergara-Alert, Júlia
AU - Lorca-Oró, Cristina
AU - Roca, Núria
AU - Fernández-Bastit, Leira
AU - Rodon, Jordi
AU - Pérez, Mònica
AU - Pradenas, Edwards
AU - Marfil, Silvia
AU - Trinité, Benjamin
AU - Ortiz, Raquel
AU - Blanco, Julià
AU - Pedroza, Jorge Díaz
AU - Carrasco, Rosa Ampudia
AU - Salgado, Yaiza Rosales
AU - Loubat-Casanovas, Jordina
AU - Larripa, Sara Capdevila
AU - Prado, Julia Garcia
AU - Barretina, Jordi
AU - Sisteré-Oró, Marta
AU - Rica, Paula Cebollada
AU - Meyerhans, Andreas
AU - Ferrer, Laura
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023/3/17
Y1 - 2023/3/17
N2 - Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4
+ and CD8
+ T cell response and RBD-binding antibodies with neutralizing activity against several variants, and also showed a good tolerability profile. Significantly, RBD fusion heterodimer vaccination conferred 100% efficacy, preventing mortality in SARS-CoV-2 infected K18-hACE2 mice, but also reducing Beta, Delta and Omicron infection in lower respiratory airways. These findings demonstrate the feasibility of this recombinant vaccine strategy.
AB - Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4
+ and CD8
+ T cell response and RBD-binding antibodies with neutralizing activity against several variants, and also showed a good tolerability profile. Significantly, RBD fusion heterodimer vaccination conferred 100% efficacy, preventing mortality in SARS-CoV-2 infected K18-hACE2 mice, but also reducing Beta, Delta and Omicron infection in lower respiratory airways. These findings demonstrate the feasibility of this recombinant vaccine strategy.
KW - SARS-CoV-2
KW - COVID-19
KW - Second-generation vaccines
KW - RBD fusion heterodimer
KW - Preclinical
KW - Mice
KW - Health sciences
KW - Immune response
KW - Immunology
KW - Microbiology
UR - https://www.scopus.com/pages/publications/85150787258
UR - https://www.mendeley.com/catalogue/1d2483e4-d349-3aef-92fc-0e61e7635f55/
U2 - 10.1016/j.isci.2023.106126
DO - 10.1016/j.isci.2023.106126
M3 - Article
C2 - 36748086
SN - 2589-0042
VL - 26
SP - 106126
JO - iScience
JF - iScience
IS - 3
M1 - 106126
ER -
ODS 3: Salud y bienestar